AstraZeneca PLC (ZEG.F)
| Previous close | 142.85 |
| Open | 143.10 |
| Bid | 140.95 x 40000 |
| Ask | 142.25 x 40000 |
| Day's range | 142.25 - 143.10 |
| 52-week range | 112.45 - 158.15 |
| Volume | |
| Avg. volume | 640 |
| Market cap | 221.237B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 38.55 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.73 (1.91%) |
| Ex-dividend date | 08 Aug 2024 |
| 1y target est | N/A |
- Business Wire
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
WILMINGTON, Del., October 03, 2024--AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
- Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
WILMINGTON, Del., October 01, 2024--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting based on positive results from the DESTI
- GlobeNewswire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.comNEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Deutsche Bank Depositary Receipts Virtual Investor Conference (“dbVIC”) held September 24th and 25th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3ZHifQf The company presentations will be available 24/7 for 90 days. Sep
